Cancer immunotherapy: Car T Cell Technology

A type of treatment in which a patient’s T cells (a type of immune cell) are altered in the laboratory so they will bind to cancer cells and destroy them. Blood from a vein in the patient’s arm flows through a tube to an apheresis machine (not shown), which eliminates the white blood cells, including the T cells, and directs the rest of the blood back to the patient. Then, the gene for a special receptor named a chimeric antigen receptor (CAR) is introduced into the T cells in the laboratory. Millions of the CAR T cells are developed in the laboratory and then given to the patient by infusion. The CAR T cells are able to bind to an antigen on the cancer cells and destroy them.

    Related Conference of Cancer immunotherapy: Car T Cell Technology

    April 28-29, 2025

    35th Experts Meet On Cancer Research & Therapy

    Paris, France
    May 26-27, 2025

    15th World Congress on Breast Cancer

    Rome, Italy
    June 16-17, 2025

    26th World Congress on Cancer Summit

    Amsterdam, Netherlands
    July 14-15, 2025

    5th World Congress on Breast Cancer

    Berlin, Germany
    July 28-29, 2025

    45th Euro Congress on Cancer Science & Therapy

    Paris, France
    August 18-19, 2025

    6th Cancer Diagnostics & Treatment Conference

    Rome, Italy
    October 13-14, 2025

    8th International Conference on Anti-Cancer Drugs & Therapies

    Aix-en-Provence, France
    October 20-21, 2025

    21st International Conference on Cancer Research

    Barcelona, Spain
    November 24-25, 2025

    43rd World Cancer Conference

    Barcelona, Spain

    Cancer immunotherapy: Car T Cell Technology Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in